文献速递前列腺癌

超极化13C-丙酮酸MRI实时检测前列腺癌骨和肝转移的代谢通量:一项临床可行性研究

Hyperpolarized 13C-pyruvate MRI detects real-time metabolic flux in prostate cancer metastases to bone and liver: a clinical feasibility study.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2019-11-04

这项试点临床研究纳入6例转移性去势抵抗性前列腺癌患者,在临床3T MRI下注射250 mM超极化13C-丙酮酸后计算丙酮酸-乳酸转化率(kPL),并配对转移灶活检行病理和RNA-seq分析。结果显示骨转移(N=4)平均kPL为0.020±0.006 s-1、肝转移(N=2)为0.026±0.000 s-1;高kPL与活检证实的髙级别前列腺癌(含1例神经内分泌分化)一致,1例肝转移在紫杉烷联合铂类化疗开始2个月后kPL从0.026降至0.015 s-1。结论认为该技术可实时检测转移灶糖酵解代谢并早期定量反映治疗反应。

要点

  • 超极化13C-丙酮酸MRI可在临床3T设备上检测前列腺癌骨和肝转移的糖酵解通量。
  • 转移灶kPL与活检髙级别病理(含神经内分泌分化)具有一致性。
  • 化疗后早期肝转移kPL可从0.026降至0.015 s-1,提示可定量监测治疗反应。

核心结论

  • 超极化13C-丙酮酸MRI可检测前列腺癌转移灶内的实时糖酵解代谢,并能在早期时间点测量治疗反应后kPL的定量变化。
  • 该首次可行性研究支持未来在晚期前列腺癌中开展超极化13C-丙酮酸MRI的临床研究。

研究设计与样本

  • 试点临床可行性研究,招募6例转移性去势抵抗性前列腺癌患者。
  • 在临床3T MRI下注射250 mM超极化13C-丙酮酸后行碳-13 MR检查,计算丙酮酸-乳酸转化率(kPL)。
  • 对配对转移灶行活检,并进行组织病理学和RNA-seq分析。

主要发现

  • 前列腺癌转移灶显示高糖酵解代谢率,骨转移(N=4)平均kPL为0.020±0.006 s-1,肝转移(N=2)为0.026±0.000 s-1。
  • 总体高kPL与活检证实的髙级别前列腺癌一致,包括1例神经内分泌分化。
  • 1例肝转移在紫杉烷联合铂类化疗开始2个月后,kPL从基线0.026降至0.015 s-1。
  • RNA-seq发现乳酸脱氢酶A亚型(Ldha)表达水平为15.7±0.7,高于丙酮酸脱氢酶主要亚型(Pdha1)的12.8±0.9。

关键数值与推荐

  • 注射用超极化13C-丙酮酸浓度为250 mM。
  • 骨转移(N=4)平均kPL为0.020±0.006 s-1,肝转移(N=2)为0.026±0.000 s-1。
  • 1例肝转移化疗后kPL从0.026降至0.015 s-1。
  • RNA-seq中Ldha表达为15.7±0.7,Pdha1表达为12.8±0.9。

临床怎么用

  • 在前列腺癌骨和肝转移患者中,可尝试用超极化13C-丙酮酸MRI无创评估糖酵解代谢通量。
  • kPL可作为早期定量监测化疗等治疗反应的候选影像生物标志物,但需未来临床研究验证。

局限性

  • 本研究为小样本试点可行性研究,共纳入6例患者。
  • 骨转移和肝转移亚组样本量分别仅为4例和2例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hyperpolarized (HP) 13C-pyruvate MRI is a stable-isotope molecular imaging modality that provides real-time assessment of the rate of metabolism through glycolytic pathways in human prostate cancer. Heretofore this imaging modality has been successfully utilized in prostate cancer only in localized disease. This pilot clinical study investigated the feasibility and imaging performance of HP 13C-pyruvate MR metabolic imaging in prostate cancer patients with metastases to the bone and/or viscera. METHODS: Six patients who had metastatic castration-resistant prostate cancer were recruited. Carbon-13 MR examination were conducted on a clinical 3T MRI following injection of 250 mM hyperpolarized 13C-pyruvate, where pyruvate-to-lactate conversion rate (kPL) was calculated. Paired metastatic tumor biopsy was performed with histopathological and RNA-seq analyses. RESULTS: We observed a high rate of glycolytic metabolism in prostate cancer metastases, with a mean kPL value of 0.020 ± 0.006 (s-1) and 0.026 ± 0.000 (s-1) in bone (N = 4) and liver (N = 2) metastases, respectively. Overall, high kPL showed concordance with biopsy-confirmed high-grade prostate cancer including neuroendocrine differentiation in one case. Interval decrease of kPL from 0.026 at baseline to 0.015 (s-1) was observed in a liver metastasis 2 months after the initiation of taxane plus platinum chemotherapy. RNA-seq found higher levels of the lactate dehydrogenase isoform A (Ldha,15.7 ± 0.7) expression relative to the dominant isoform of pyruvate dehydrogenase (Pdha1, 12.8 ± 0.9). CONCLUSIONS: HP 13C-pyruvate MRI can detect real-time glycolytic metabolism within prostate cancer metastases, and can measure changes in quantitative kPL values following treatment response at early time points. This first feasibility study supports future clinical studies of HP 13C-pyruvate MRI in the setting of advanced prostate cancer.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Chen HY, Aggarwal R, Bok RA, et al. Hyperpolarized 13C-pyruvate MRI detects real-time metabolic flux in prostate cancer metastases to bone and liver: a clinical feasibility study. Prostate Cancer Prostatic Dis. 2019. PMID: 31685983. doi:10.1038/s41391-019-0180-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。